Literature DB >> 10842093

Integrins and signaling in osteoclast function.

L T Duong1, P Lakkakorpi, I Nakamura, G A Rodan.   

Abstract

Integrins are heterodimeric adhesion receptors that mediate cell-matrix and cell-cell interactions. Osteoclasts highly express the alphavbeta3 integrin, which binds to a variety of extracellular matrix proteins including vitronectin, osteopontin and bone sialoprotein. RGD-containing peptides, RGD-mimetics and alphavbeta3 blocking antibodies inhibit bone resorption in vitro and in vivo, suggesting that this integrin plays an important role in osteoclast function. RGD-containing peptides were shown to raise cytosolic calcium in osteoclasts. Furthermore, several signaling and adaptor molecules were found to be involved in alphavbeta3 integrin-dependent signaling pathways, including phosphatidylinositol 3-kinase, c-Src, PYK2 and p130(cas). In addition, cytoskeletal molecules such as paxillin, vinculin, gelsolin and F-actin are recruited to adhesion contacts upon integrin activation. Many of these molecules signaling and cytoskeletal localize to the sealing zone of actively resorbing osteoclasts, suggesting that they play a role in linking the adhesion of osteoclasts to the bone matrix with the cytoskeletal organization and the polarization and activation of these cells for bone resorption.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842093     DOI: 10.1016/s0945-053x(00)00051-2

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  54 in total

1.  Approaches to studying cellular signaling: a primer for morphologists.

Authors:  Kathy Kay Hartford Svoboda; Wende R Reenstra
Journal:  Anat Rec       Date:  2002-04-15

2.  Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts.

Authors:  Tao Ma; Kavitha Sadashivaiah; Nandakumar Madayiputhiya; Meenakshi A Chellaiah
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

3.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

Review 4.  Breaking new ground to build bone.

Authors:  Lauren A Kingsley; John M Chirgwin; Theresa A Guise
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-20       Impact factor: 11.205

Review 5.  Bone cell-matrix protein interactions.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

Review 6.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

7.  Bioceramics composition modulate resorption of human osteoclasts.

Authors:  Y Ramaswamy; D R Haynes; G Berger; R Gildenhaar; H Lucas; C Holding; H Zreiqat
Journal:  J Mater Sci Mater Med       Date:  2005-12       Impact factor: 3.896

8.  Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.

Authors:  Xuanyu Lu; Yoshihiro Ito; Phimon Atsawasuwan; Smit Dangaria; Xiulin Yan; Tuojiang Wu; Carla A Evans; Xianghong Luan
Journal:  Bone       Date:  2013-02-04       Impact factor: 4.398

9.  Myosin X regulates sealing zone patterning in osteoclasts through linkage of podosomes and microtubules.

Authors:  Brooke K McMichael; Richard E Cheney; Beth S Lee
Journal:  J Biol Chem       Date:  2010-01-17       Impact factor: 5.157

10.  Locomotion guidance by extracellular matrix is adaptive and can be restored by a transient change in Ca2+ level.

Authors:  Hong-Wen Liu; Yun-Cin Luo; Chia-Lin Ho; Jung-Yen Yang; Chi-Hung Lin
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.